Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - NRAP |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - NRAP | intrahepatic cholangiocarcinoma | sensitive | Futibatinib | Case Reports/Case Series | Actionable | In a Phase I trial, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-NRAP fusion responded to TAS-120 for 17.2 months before progressing due to an acquired FGFR2 N550K mutation, detected in cell-free DNA and the tumor biopsy (PMID: 31109923; NCT02052778). | 31109923 | |
FGFR2 - NRAP | cholangiocarcinoma | predicted - sensitive | Infigratinib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with Truseltiq (infigratinib) resulted in stable disease for seven months in a patient with cholangiocarcinoma harboring an FGFR2-NRAP fusion (PMID: 34250419). | 34250419 | |
FGFR2 - NRAP | intrahepatic cholangiocarcinoma | sensitive | Infigratinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-NRAP fusion responded to Truseltiq (infigratinib) for 7.1 months before progressing (PMID: 31109923). | 31109923 | |
FGFR2 - NRAP | Advanced Solid Tumor | sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Pemazyre (pemigatinib) treatment decreased viability of transformed cells expressing FGFR2-NRAP in culture (PMID: 35176488). | 35176488 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|